The elevated P/S multiple suggests that investors are discounting future commercial success rather than current financial performance. This valuation warrants caution, as any regulatory setback or delay in the launch of revumenib could lead to a significant compression of these multiples, given the lack of a stable earnings base to support the current market capitalization.

The persistent negative ROIC is a direct consequence of the heavy R&D spending required to advance the Menin-MLL inhibitor pipeline. Until the company achieves commercial scale, these returns will likely remain depressed, as the capital deployed is currently locked in long-gestation clinical assets rather than revenue-generating operations.

This erratic cycle suggests that working capital management is currently secondary to the primary objective of clinical advancement. Investors should monitor these fluctuations closely, as they obscure the underlying cash burn rate and complicate the assessment of operational efficiency until the company transitions to a more predictable commercial model.

The emergence of debt on the balance sheet introduces new interest coverage risks, particularly given the company's negative operating margins. This shift suggests that management is increasingly willing to leverage the balance sheet to extend its cash runway, which may increase financial risk if clinical milestones are not met on schedule.